Office for Technology Commercialization

Bacterial Histidine Kinase Inhibitor

Technology #20170232

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
HK inhibitorsKey interactions of ADP (orange) with different residues in the CA domain Bacterial HKs
Erin Carlson, PhD
Associate Professor, Chemistry
External Link (
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection

PCT Patent Application Filed
Inactivation of Multiple Bacterial Histidine Kinases by Targeting the ATP-Binding Domain
ACS Chem. Biol. , 2015, 10 (1), pp 328–335
Rational Design of Selective Adenine-Based Scaffolds for Inactivation of Bacterial Histidine Kinases
J. Med. Chem. , 2017, 60, 19, 8170-8182

Novel antibacterial drug targets

New compounds inhibit activity of multiple bacterial histidine kinases (HKs) and hold potential as therapeutics or antibiotics. These scaffolds could provide valuable starting points for designing broadly effective HK inhibitors, globally reducing bacterial signaling, and ultimately, developing a class of antibiotics with a new mechanism of action. HKs are one part of the bacterial two-component systems (TCSs), the primary signaling pathways bacteria use to respond to their environment. The new antibacterial compounds attenuate these signaling pathways by broadly targeting the histidine kinase family—they focus on the highly conserved ATP-binding domains in TCSs. Because HKs are very specific to bacteria, their inhibitors can target multiple types of bacteria while minimizing the possibility of human toxicity. Multi-targeted therapy may also hinder drug resistance since concurrent mutation of several drug target-encoding genes is unlikely.

New antibiotics for treating infectious disease

Bacteria have developed resistance to known antibiotics; therefore, novel therapeutics are needed to treat infections stemming from such antibiotic-resistant bacteria. New therapeutics would ideally aim for novel targets in such a way that antibiotic resistance does not rapidly develop. These new compounds circumvent bacterial resistance by targeting bacterial histidine kinases, a class of proteins not currently targeted with known drugs.

Phase of Development

  • In vitro assessment. In vitro data in whole-cell assays.


  • Decreased chance for resistance to develop
  • Decreases possibility of human toxicity
  • Targets multiple types of bacteria


  • Potential therapeutics/antibiotics
  • Targets highly conserved ATP-binding domains in bacteria
  • Targets a new class of proteins not targeted with known drugs


  • Antibiotics (specifically for drug resistant bacteria)
  • Developing a new class of antibiotics
  • Agricultural applications for treating antibiotic-resistant bacteria
  • May re-sensitize resistant bacteria to existing drugs

Interested in Licensing?
The University relies on industry partners to scale up technologies to large enough production capacity for commercial purposes. The license is available for this technology and would be for the sale, manufacture or use of products claimed by the issued patents. Please contact Kevin Anderson to share your business needs and technical interest in this technology and if you are interested in licensing the technology for further research and development.